ACUTE BIPHENOTYPIC LEUKEMIA

This study tests a new way to prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers who receive a donor stem cell transplant. Researchers remove a specific type of immune cell (naive T cells) from the donor cells before transplant to red…

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…

This early-phase study tests whether bone marrow from deceased donors can be safely used for people with blood cancers like leukemia and lymphoma. About 12 patients will receive a transplant after chemotherapy, and doctors will monitor for side effects and blood cell recovery for…

This study tests a combination of two drugs (enasidenib and azacitidine) in about 50 people with a specific genetic mutation (IDH2) and acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if the combination can stop cancer cell growth an…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or a fast-growing form of chronic myeloid leukemia. The goal is to see how well these drugs ki…